Cryotherapy to treat anogenital warts in nonimmunocompromised adults: Systematic review and meta-analysis - 12/08/17
, Nicolas Dupin, MD, PhD c, Fabrice Bouscarat, MD d, Brigitte Milpied, MD e, Christian Derancourt, MD b, f, gAbstract |
Background |
Cryotherapy is one of the most commonly used therapeutic modalities to treat anogenital warts (AGWs), but this treatment was not clearly established in the recent international recommendations.
Objective |
To compare the efficacy and safety of cryotherapy versus other AGW treatments.
Methods |
Through a systematic search of 12 electronic databases, we identified 11 randomized controlled trials, screened from database inception through October 2016, that met the inclusion criteria (including immunocompetent adults with AGWs receiving cryotherapy in 1 of the comparison groups). Primary endpoint was complete clearance of AGW. Risk-for-bias assessment was based on Cochrane Handbook recommendations. Meta-analyses used Review Manager v5.3 software.
Results |
Cryotherapy efficacy did not appear to differ from that of trichloroacetic acid, podophyllin, or imiquimod. Electrosurgery was weakly associated with better AGW clearance than cryotherapy (risk ratio [RR] 0.80, 95% confidence interval [CI] 0.65-0.99). Cryotherapy was associated with more immediate low-level adverse events (erythema, stinging, or irritation; RR 3.02, 95% CI 1.38-6.61) and immediate pain requiring oral analgesics (RR 2.11, 95% CI 1.07-4.17) but fewer erosions (RR 0.57, 95% CI 0.36-0.90).
Limitations |
All but 1 randomized-controlled trial had a high risk for bias.
Conclusion |
With low-level quality of the evidence, cryotherapy is an acceptable first-line therapy to treat AGWs.
Le texte complet de cet article est disponible en PDF.Key words : anogenital warts, condyloma, cryotherapy, genital, HPV, infection, meta-analysis, penile, sexually transmitted disease, STD, systematic review, vulvar
Abbreviations used : AE, AGW, CI, GRADE, HPV, ITT, KOH, OR, PRISMA, RCT, RR, TCA
Plan
| Funding sources: Supported by grants from the Fondation pour la Recherche Médicale (no. DEA20140630698) and the Programme Hospitalier de Recherche Clinique Interrégional (no. 13-069). |
|
| Conflicts of interest: None declared. |
|
| Previously presented: Some study results were presented on a poster at the Journées Nationales d’Infectiologie in Lille, France, June 7-9, 2016 (Bertolotti et al. Med Mal Infect. 2016;46:72). |
Vol 77 - N° 3
P. 518-526 - septembre 2017 Retour au numéro
Article précédent
- Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients
- Jorre S. Mertens, Rogier M. Thurlings, Wietske Kievit, Marieke M.B. Seyger, Timothy R.D. Radstake, Elke M.G.J. de Jong
- Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck
- Juana María García-Pedrero, Pablo Martínez-Camblor, Susana Diaz-Coto, Pablo Munguia-Calzada, Aitana Vallina-Alvarez, Francisco Vazquez-Lopez, Juan Pablo Rodrigo, Jorge Santos-Juanes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?